The combination tetracycline-streptomycin has been proposed by the World Health Organization (WHO) as the treatment of choice for human brucellosis (11) .
However, this mode of antibiotic therapy, giving tetracycline chlorhydrate for 3 weeks and streptomycin for 2 weeks, has not achieved the complete eradication of the disease in some patients, who presented with a relapse in the months immediately after treatment, in particular those in whom the disease was caused by Brucella melitensis (25) .
During the last decade, there have been several trials with other antibiotics for the treatment of brucellosis in an attempt to avoid the relapses and the inconvenience of intramuscular streptomycin administration and the toxicity of the classical treatment. Recently, the oral administration of rifampin-doxycycline has been suggested as a promising alternative therapy for human brucellosis (6) , but there is as yet little clinical experience with this combination, and the optimal duration of treatment remains still undetermined.
In an attempt to compare the efficacy of rifampindoxycycline versus tetracycline-streptomycin, we have undertaken a prospective, randomized trial in which both combinations were administered during a 30-day period, similar to the duration of therapy advised by the WHO. For patients with focal disease from either group, oral treatment with tetracycline hydrochloride or doxycycline and rifampin was prolonged for 45 days, and streptomycin was maintained for 21 days. The study was initially designed to include a large number of patients, but the high percentage of relapses in group B prompted us to abandon it for ethical reasons; thus, a matching number of patients in both groups was not achieved.
MATERIALS AND METHODS

Patients
Foliow-up. At least four blood samples for culture were taken from each patient before therapy was started, and all patients were carefully evaluated during treatment. Samples for blood culture were also taken on days 7 and 15 of treatment.
After being discharged from the hospital, patients were asked to return on an outpatient basis. Routine blood cultures and serological and clinical evaluations were done monthly during the first 3 months posttherapy and every 3 months thereafter over a 1-or 2-year period.
Statistical analysis. The chi-square test with Yates correction and the exact Fischer test were used for statistical analysis.
RESULTS
Patients. Four patients from group A and six from group B were excluded because they did not take the prescribed drugs correctly (five patients) or had a follow-up of less than 6 months (five patients). The final number of patients in group A was 28 (15 received tetracycline hydrochloride, and 13 received' oxycycline), and the final number in group B was 18. There were 22 men and 6 women with ages ranging from 13 to 61 years (mean ± SD, 33 ± 14 years) in group A and 14 men and 4 women aged from 12 to 54 years (34 + 14 years) in group B. Twenty-four patients from group A and 17 from group B had blood cultures positive for B. melitensis before therapy. Six patients from group A had focal disease, including sacroiliitis (three patients), spondylitis (one patient), liver abscess (one patient), and orchitis (one patient), as did four patients from group B who had sacroiliitis (one patient), spondylitis (one patient), prostatitis (one patient), and orchitis (one patient). The duration of symptoms before therapy ranged from 6 to 180 days (mean ± SD, 38 + 47 days) in group A and from 7 to 60 days (26 ± 24 days) in group B. The follow-up period for group A was from 6 to 23 months (mean ± SD, 16 ± 5 months) and from 6 to 24 months for group B (16 ± 6 months).
Response to therapy. Both groups showed a favorable clinical response during therapy. The defervescence period was from 1 to 6 days for group A (mean ± SD, 3.1 ± 1.2 days) and from 1 to 4 days for group B (2.6 ± 1.1 days).
There were no therapeutic failures. During treatment, positive blood cultures persisted in two patients from group A at days 7 and 15, respectively, although both had become asymptomatic. Nevertheless, both patients recovered without relapse, and blood cultures became negative shortly afterwards. All blood cultures for group B were negative during treatment.
Two patients from group A (7.1%) had relapses at 6 and 7 months posttherapy, respectively, whereas seven patients from group B (38.8%) (P = 0.024) had relapses at 1 month (1 patient), 2 months (5 patients), and 3 months (1 patient) posttherapy. None of the patients with focal disease who had been treated for 45 days (6 patients in group A; 4 The study of the antibiotic susceptibility performed in six of the nine cases (one in group A and five in group B) showed the same susceptibility in initial isolates and strains isolated after relapse (data not shown).
DISCUSSION
In vitro studies have shown that the majority of Brucella spp. strains are very susceptible to rifampin (7, 10) . In addition, the excellent penetration into the cells (16; F. Regnier, These de Medicine, Universite de Montpellier, Montpellier, France, 1978) and the satisfactory results obtained in trials with experimentally induced brucella in mice (21) suggest that rifampin might be useful in the therapy of brucella infections in humans. Based on preliminary study results, some authors claim that rifampin alone may be an effective mode of therapy for human brucellosis (1, 13-15, 19, 20, 26) . However, in the majority of those studies, rifampin was administered over long periods, very heterogeneously, and with only short-term follow-up for relapses. In contrast, other authors (6, 23) state that brucellosis should not be treated with rifampin alone because of the high number of relapses. Because of this and because of the possibility that brucella strains may become resistant to rifampin during treatment as occurs in other infections, an association with other antibiotics has been suggested (6).
ANTIMICROB. AGENTS CHEMOTHER. The combination of rifampin and trimethoprim tested in the therapy of brucellosis induced in mice (22) gave poor results, as it did in human brucellosis (J. Ariza, F. Gudiol, P. Fernandez Viladrich, J. Garau, G. Rufi, and J. Lifiares, 3rd
Mediterr. Congr. Chemother. abstract no. 54, 442, 1982). Over recent years, the combination of rifampin-doxycycline has been suggested as an effective mode of therapy for brucellosis (5) . Some in vitro studies have shown a synergistic activity of this antibiotic association against the majority of B. melitensis strains (6) . However, reports regarding the treatment of brucellosis in humans with this combination have been limited to only a few studies (5, Greece, abstr. no. 275, 1984) . However, the antibiotic combinations were administered for 45 days rather than the shorter periods classically recommended. The rate of relapse reported for B. melitensis brucellosis treated with the WHO-recommended schedule of tetracycline for 3 weeks and streptomycin for 2 weeks is approximately 15% (8, 17) . Because of the possibility that tetracycline administered over longer periods might result in a lower relapse rate (3, 4), we decided on a 30-day antibiotic regime for patients without focal disease and a 45-day regime for patients with focal disease.
The initial response to therapy, the return to negative blood cultures, and the absence of therapeutic failures were similar in both groups.
Although we do not have a satisfactory explanation for the persistence of bacteremia at days 7 and 15 of therapy in two patients from group A, it did not appear to be of major importance with respect to final outcome, because neither patient relapsed, both became symptom free, and blood cultures became negative and have remained so until the present. These patients were therefore classified as cured.
Although the initial response to therapy was satisfactory, The evaluation of the efficacy of antibiotic modalities in the therapy of brucellosis is complicated by the characteristics of the disease which may at times make it difficult to correctly assess clinical findings and determine the true rate of relapses.
Our findings of few symptoms in patients who presented with relapse, relapse manifesting at 6 and 7 months posttherapy in two of our patients, and blood cultures becoming positive before the appearance of clinical symptoms of relapse in three cases all emphasize the need for rigorous and prolonged follow-up for relapses.
The difference between a true relapse and reinfection must also be taken into account. The majority of our patients who presented with relapse had symptoms within the first 2 months posttherapy; of the nine, only one worked under conditions favoring occupational disease, and it would therefore appear that the majority were true relapses rather than reinfections.
Both antibiotic regimes used in our study were usually well tolerated; only a few patients in group A had symptoms of mild intolerance or toxicity with tetracycline-streptomycin. Patients in group B showed good tolerance of the rifampin-doxycycline regime. However, the last is of little clinical importance and is not by itself a reason for recommending the combination over the classically recommended mode of therapy for brucellosis. From our results with this study, we concluded that oral rifampin-doxycycline taken for 1 month is a well-tolerated and comfortable mode of therapy for patients with brucellosis and can elicit an initial clinical improvement; however, the relapse rate is too high, and a more prolonged period of treatment appears to be necessary with this combination to obtain the low number of relapses achieved with the classically recommended treatment with tetracycline and streptomycin.
